FDA Advisory Committee recommends Shingrix vaccine for the prevention of herpes zoster (shingles) in adults ages 50 and over.- GSK.
GlaxoSmithKline plc announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the FDA voted unanimously that the data support the efficacy and safety of Shingrix for the prevention of herpes zoster (shingles) in adults ages 50 and over. FDA Advisory Committees provide non-binding recommendations for consideration by the FDA, with the final decision on approval made by the FDA.
GSK�s shingles candidate vaccine is not currently approved for use anywhere in the world. Regulatory filings in the European Union, Canada, Australia and Japan are underway.
.Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.